Physician profile
Willie Gilbert
NPI 1861804205
$3,096.94
in general payments reported to CMS, 2019-2025
23 companies · $1,532 in 2025
The $1,532 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $130 · 2024: $1,436 · 2025: $1,532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,097.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,096.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,172.05 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $528.14 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Janssen Biotech, INC. | $189.32 | 2025 | Tremfya |
| Otsuka America Pharmaceutical, INC. | $162.77 | 2023-2025 | Rexulti |
| Gilead Sciences, INC. | $126.72 | 2024-2025 | Epclusa |
| Exact Sciences Corporation | $114.57 | 2024-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $91.67 | 2025 | Wegovy |
| Shield Therapeutics INC | $88.29 | 2024-2025 | |
| Axsome Therapeutics, INC. | $82.13 | 2024 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.66 | 2024 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $57.92 | 2024-2025 | Caplyta |
| Pfizer INC. | $56.67 | 2024-2025 | |
| Glaxosmithkline, LLC. | $54.47 | 2023-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $51.92 | 2023-2025 | Mounjaro |
| Xeris Pharmaceuticals, INC. | $51.83 | 2024 | Gvoke Hypopen |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $47.72 | 2024 | Trintellix |
| Amgen INC. | $44.18 | 2023-2025 | Repatha, Otezla, Otezla |
| Insulet Corporation | $40.54 | 2024 | Omnipod |
| Esperion Therapeutics, INC. | $19.83 | 2024 | Nexletol |
| Intercept Pharmaceuticals, INC. | $17.09 | 2025 | |
| Phathom Pharmaceuticals, INC. | $14.38 | 2025 | Voquezna |
| Paratek Pharmaceuticals, INC. | $13.78 | 2024 | Nuzyra |
| Dynavax Technologies Corporation | $9.29 | 2023 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Willie Gilbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.